The Johnson & Johnson story
What drives Johnson & Johnson, what its price assumes and what could change the story, written from its own filings.
- Medicines drive growth. Innovative Medicine posted 7.9% operational growth in the quarter to September 2026 despite a substantial drag from STELARA.
- Talc clouds earnings. Reported earnings per share were $0.09 in the quarter to September 2026, reflecting the proposed talc resolution and business development transactions, versus adjusted earnings per share of $2.59.
- Faster cash growth required. The share price implies free cash flow after stock pay growing 12.6% a year for ten years, compared with 2.4% a year delivered over the last 10 years.
